Open Access

The emergence of a novel sequence type of MDR Acinetobacter baumannii from the intensive care unit of an Egyptian tertiary care hospital

  • Doaa Mohammad Ghaith1,
  • Mai Mahmoud Zafer2,
  • Mohamed Hamed Al-Agamy3, 4Email author,
  • Essam J. Alyamani5,
  • Rayan Y. Booq5 and
  • Omar Almoazzamy6
Annals of Clinical Microbiology and Antimicrobials201716:34

DOI: 10.1186/s12941-017-0208-y

Received: 14 December 2016

Accepted: 12 April 2017

Published: 10 May 2017

Abstract

Background and aim of work

Acinetobacter baumannii is known for nosocomial outbreaks worldwide. In this study, we aimed to investigate the antibiotic susceptibility patterns and the clonal relationship of A. baumannii isolates from the intensive care unit (ICU) of an Egyptian hospital.

Methods

In the present study, 50 clinical isolates of multidrug resistant (MDR)-A. baumannii were obtained from patients admitted into the ICU from June to December 2015. All isolates were analyzed for antimicrobial susceptibilities. Multiplex PCR was performed to detect genes encoding oxacillinase genes (bla OXA-51-like, bla OXA-23-like, bla OXA-24-like, and bla OXA-58-like). Multilocus sequence typing (MLST) based on the seven-gene scheme (gltA, gyrB, gdhB, recA, cpn60, gpi, rpoD) was used to examine these isolates.

Results

All A. baumannii clinical isolates showed the same resistance pattern, characterized by resistance to most common antibiotics including imipenem (MIC ≥ 8μ/mL), with the only exception being colistin. Most isolates were positive for bla OXA-51-like and bla OXA-23-like (100 and 96%, respectively); however, bla OXA-24-like and bla OXA-58-like were not detected. MLST analysis identified different sequence types (ST195, ST208, ST231, ST441, ST499, and ST723) and a new sequence type (ST13929) with other sporadic strains.

Conclusions

MDR A. baumannii strains harboring bla OXA-23-like genes were widely circulating in this ICU. MLST was a powerful tool for identifying and epidemiologically typing our strains. Strict infection control measures must be implemented to contain the worldwide spread of MDR A. baumannii in ICUs.

Keywords

MDR- A. baumannii bla OXA-23-like MLST

Background

The clinical care of intensive care unit (ICU) patients with infections has been complicated by the emergence and spread of extremely drug-resistant (XDR) Acinetobacter baumannii strains [1]. Due to scarce current therapeutic options; higher infection rates; poor patient outcomes because of life-threatening infections, including ventilator-related pneumonia, sepsis, urinary tract infections, and skin and soft tissue disorders may occur [1, 2].

Extensively drug-resistant (XDR) A. baumannii strains exhibiting resistance to three or more antibiotic classes, except for polymyxins, have been recently described in nosocomial outbreaks [2, 3]. The essential role of A. baumannii resistance to carbapenems, is mediated by oxacillinases (OXA-class D) and, less frequently, by metallo-β-lactamases (MBL-class B) [4, 5]. The class D carbapenemases are the most predominant carbapenemases in A. baumannii. They are categorized into six subclasses: intrinsic chromosomal OXA-51-like, the acquired OXA-23-like, OXA-24/40-like, OXA-58-like, OXA-143-like, and OXA-235-like β-lactamases [6]. In this study, we aimed to investigate the antimicrobial susceptibility, class D carbapenemases and clonal relationship of A. baumannii strains isolated from a tertiary care hospital ICU in Egypt.

Methods

The study was carried out in EL Sheikh Zayed hospital which provides tertiary care from specialists and consultants after referral (in orthopedic, trauma, neuro/spine surgeries) from primary care and secondary care hospitals in Egypt. A lab-based surveillance was performed over a period of 6 months (June–December 2015) after the isolation of five MDR A. baumannii strains in a period of 1 week showing the same phenotypic characteristics.

Bacterial strains

All clinical samples of the patients admitted during the above-mentioned period were processed at the microbiology unit. All samples were cultured on blood agar and MacConkey agar (Oxoid Co. England). All culture plates were incubated aerobically at 35 °C for 24–48 h. Identification of isolated organisms was performed by conventional biochemical reactions. During the experimental period, 50 A. baumannii non-duplicate strains were isolated.

Antimicrobial susceptibility testing

Susceptibility testing was performed by the disc diffusion method (Modified Kirby-Bauer technique) using Mueller–Hinton agar and aerobic incubation at 35 °C for 16–18 h. Antimicrobial discs containing imipenem (10 μg), meropenem (10 μg), gentamicin (10 μg), ciprofloxacin (5 μg), amikacin (30 μg), cotrimoxazole (25 μg), cefepime (30 μg), cefotaxime (30 μg), cefotaxime/clavulanic acid (30/10 μg), aztreonam (30 μg), ceftazidime (30 μg), ceftazidime/clavulanic acid (30/10 μg), amoxicillin/clavulanic acid (20/10 μg), and cefoxitin (30 μg) were obtained from Oxoid Co. (Oxoid Limited, Basingstoke, Hampshire, England) [7].

Multidrug resistance was defined in this analysis as resistance to three or more representatives of the following classes of antibiotics: fluoroquinolones, extended-spectrum cephalosporins, aminoglycosides, and carbapenems [8].

Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, and Staphylococcus aureus ATCC 29213 were used as reference strains for susceptibility testing per Clinical and Laboratory Standards Institute (CLSI, 2015) guidelines and interpretations [7].

Minimum inhibitory concentrations (MICs) were determined by broth microdilution and interpreted using CLSI, 2015 guidelines [7].

The presence of A. baumannii genes encoding oxacillinases (bla OXA-23-like, bla OXA-24-like, bla OXA-51-like, and bla OXA-58-like) was assessed in all 50 isolates using multiplex PCR.

Multiplex PCR assay

The sequences of bla OXA alleles encoding carbapenemases were aligned and group-specific regions were identified using BioEdit software (http://www.mbio.ncsu.edu/BioEdit/bioedit.html). The primers: 5′-TAA TGC TTT GATCGG CCT TG and 5′-TGG ATT GCA CTT CAT CTT GG were used to amplify a 353 bp fragment of genes encoding the intrinsic OXA-51-like enzymes of A. baumannii [9].

A set of primers were designed to amplify OXA-23-like genes (501 bp: 5′-GAT CGG ATT GGA GAA CCAGA and 5′-ATT TCT GAC CGC ATT TCC AT), OXA-24-like genes (246 bp: 5′-GGT TAG TTG GCC CCC TTA AA and 5′-AGT TGA GCG AAA AGG GGA TT), and OXA-58-like genes (599 bp: 5′-AAG TAT TGG GGC TTG TGC TG and 5′-CCCCTCTGCGCTCTACATAC) [9]. The primers were evaluated separately against control strains and then in a multiplex format. The amplification conditions were: initial denaturation at 94 °C for 5 min, 30 cycles of 94 °C for 25 s, 52 °C for 40 s, and 72 °C for 50 s, and a final elongation at 72 °C for 6 min [9].

Multilocus sequence typing

MLST analysis was performed per the protocol of the Pasteur Institute. Fragments of seven internal housekeeping genes (gltA, gyrB, gdhB, recA, cpn60, gpi, and rpoD) were amplified and sequenced as previously described [10]. Briefly, PCR amplifications were performed with a MasterCycler Nexus (Eppendorf, Hamburg, Germany) with an initial denaturation at 94 °C for 5 min, followed by 35 cycles of denaturation at 94 °C for 1 min, annealing at 55 °C for 1 min, and extension at 72 °C for 2 min, and a 4-min final extension at 72 °C. The amplicons were verified by agarose gel electrophoresis and were subsequently purified for bidirectional Sanger sequencing reactions. Multiple allele sequences were assigned for each locus with an arbitrary allele number to obtain characterization of sequence types (STs) for each A. baumannii isolate. Each sequence was compared with sequences deposited in the Institute of Pasteur MLST schema (http://pubmlst.org/perl/bigsdb/bigsdb.pl?db=pubmlst_abaumannii_pasteur_seqdef).

Results

Out of 358 patients admitted to ICU from June to December 2015, 56 (15.6%) patients were diagnosed with various types of hospital-acquired infections (HAI) as shown in Table 1. A total of 50 non-duplicate A. baumannii strains were isolated from different patient samples. Phenotypic antibiotic susceptibility testing for all A. baumannii isolates showed the same drug resistance pattern, characterized by resistance to all antibiotics used including imipenem, except for colistin. Genotypic analysis of bla OXA-51-like, bla OXA-23-like, bla OXA-24-like, and bla OXA-58-like genes by multiplex PCR (Fig. 1) showed that bla OXA-51-like and bla OXA-23-like were the most prevalent genes with 100 and 96% prevalence, respectively. However, bla OXA-24-like and bla OXA-58-like were not detected in the current study. Multilocus sequence typing (MLST) of the 50 clinical isolates of A. baumannii has yielded different sequence types; ST195, ST208, ST231, ST441, ST499, and ST723. Interestingly, a new sequence type ST13929 was identified among A. baumannii clinical isolates as shown in Table 2 and Fig. 2. A. baumannii ST13929 has been isolated from a young male (21 years old) patient who had no history of overseas travel. He was admitted to ICU at El Sheikh Zayed Specialized Hospital, Giza, Egypt on 5th of December 2014. The patient had multiple traumas due to motor car accident. After 7 days of ventilation the patient diagnosed to have ventilator associated pneumonia (VAP). Empirical antibiotic therapy of intravenous ceftriaxone/cefotaxime had been initiated. Endotracheal aspiration has been cultured on blood, chocolate and MacConkey agars. The recovered colonies had been identified as A. baumannii. Further genotypic identification was done by restriction analysis of 16S–23S rRNA spacer sequences using AluI and NdeII. The isolate exhibited XDR towards imipenem (MIC > 32 mg/L), meropenem (MIC > 32 mg/L), ceftazidime (>256 mg/L), cefepime (MICs > 256 mg/L), gentamicin (MICs > 256 mg/L), amikacin (MICs > 256 mg/L), and ciprofloxacin (MICs > 32 mg/L). Tigecycline susceptibility was observed at MIC of 1 mg/L. The antimicrobial therapy was changed to tigecycline on day 11. The patient had spent 107 days in the hospital. The patient was alive after the hospitalization period. There was an ongoing XDR- A. baumannii outbreak in the institution in the same period and multiple isolates had been investigated.
Table 1

Patient’s data

 

Age (mean ± SD)

Sex %

APACHE  %

Length of stay (mean ± SD)

More than one device inserted %

Male

Female

<15%

>15%

VAP

(42.62 ± 17.63)

72%

28%

40%

60%

(48.96 ± 77.3)

(100%)

CLABSI

(41 ± 23.4)

88.8%

11.1%

33.3%

66.6%

(22.33 ± 11.4)

(55.55%)

CAUTI

(44.53 ± 22.1)

76.9%

23.0%

38.4%

61.5%

(82.307 ± 67.8)

(100%)

P value

0.900

0.535

0.880

0.131

0.00

VAP ventilator associated pneumonia, CLABSI central line associated blood stream infection, CAUTI catheter associated urinary tract infection, APACHI acute physiology and chronic health evaluation

Fig. 1

Results of multiplex PCR for detection of bla OXA-51-like, bla OXA-23-like, bla OXA-24-like, and bla OXA-58-like genes. Lane 1 100 bp DNA Ladder, Lane 2 positive control, Lanes 36 A. baumannii clinical isolates showing bla OXA-51-like and bla OXA-23-like positivity (353 and 501 bp, respectively). bla OXA-24-like and bla OXA-58-like were not detected at (246 and 599 bp) respectively. Lane 7 negative control

Table 2

Sequence types (STs), allele profiles of 50 carbapenem-resistant A. baumannii isolates, carbapenem-hydrolyzing class D β-lactamase genes, minimum inhibitory concentration (MIC), site of isolation and patient outcome

 

Sample ID

Site of isolation

Allele profile

ST

Carbapenem-hydrolyzing class D β-lactamase genes

MIC R ≥ 8 (mg/L)

Patient outcome

gltA

gyrB

gdhB

recA

cpn60

gpi

rpoD

bla OXA-51

bla OXA-23

bla OXA-24

bla OXA-58

IMI

A. baumannii

21

ETA

1

3

3

2

2

96

3

195

+

+

25

Deceased

A. baumannii

22

ETA

1

3

3

2

2

96

3

195

+

+

20

Deceased

A. baumannii

30

ETA

1

3

3

2

2

97

3

208

+

+

25

Deceased

A. baumannii

33

ETA

1

3

No gene

2

2

97

3

NA

+

+

25

Deceased

A. baumannii

34

ETA

1

3

3

2

2

97

3

208

+

35

Deceased

A. baumannii

36

ETA

1

3

3

2

2

97

3

208

+

+

20

Deceased

A. baumannii

37

ETA

1

3

3

2

2

97

3

208

+

+

30

Deceased

A. baumannii

44

Blood

1

3

3

2

2

97

3

208

+

+

25

Deceased

A. baumannii

46

Urine

1

3

3

2

2

97

3

208

+

+

25

Deceased

A. baumannii

47

Urine

1

3

No gene

2

2

97

3

NA

+

+

30

Discharged

A. baumannii

49

Urine

1

3

3

2

2

96

3

195

+

+

25

Deceased

A. baumannii

5

ETA

1

12

3

2

2

79

3

1114

+

+

20

Deceased

A. baumannii

29

ETA

1

87

3

2

2

96

3

13929a 

+

+

20

Discharged

A. baumannii

24

ETA

1

107

12

10

23

195

26

723

+

+

25

Deceased

A. baumannii

25

ETA

1

107

12

10

23

195

26

723

+

+

25

Deceased

A. baumannii

38

ETA

1

107

12

10

23

195

26

723

+

+

30

Deceased

A. baumannii

48

urine

1

107

12

10

23

195

26

723

+

+

25

Deceased

A. baumannii

1

ETA

10

12

4

11

4

100

5

441

+

+

30

Deceased

A. baumannii

3

ETA

10

12

4

11

4

79

5

945

+

+

15

Deceased

A. baumannii

4

ETA

10

12

4

11

4

100

5

441

+

+

35

Discharged

A. baumannii

8

ETA

10

12

4

11

4

100

5

441

+

+

35

Deceased

A. baumannii

11

ETA

10

12

4

11

4

100

5

441

+

+

20

Deceased

A. baumannii

14

ETA

10

12

4

11

4

100

5

441

+

+

20

Deceased

A. baumannii

16

ETA

10

12

4

11

4

100

5

441

+

+

25

Discharged

A. baumanii

18

ETA

10

12

No gene

11

4

98

5

NA

+

+

20

Deceased

A. baumanii

19

ETA

10

12

4

11

4

98

5

231

+

+

20

Deceased

A. baumannii

20

ETA

10

12

4

11

4

98

5

231

+

+

20

Deceased

A. baumannii

23

ETA

10

12

4

11

4

98

5

231

+

+

15

Deceased

A. baumannii

26

ETA

10

12

4

11

4

98

5

231

+

+

25

Deceased

A. baumannii

27

ETA

10

12

4

11

4

98

5

231

+

+

20

Deceased

A. baumannii

28

ETA

10

12

4

11

4

98

5

231

+

+

20

Deceased

A. baumannii

31

ETA

10

12

4

11

4

100

5

441

+

+

25

Deceased

A. baumannii

32

ETA

10

12

4

11

4

98

5

231

+

+

20

Deceased

A. baumannii

35

ETA

10

12

4

11

4

98

5

231

+

+

25

Deceased

A. baumannii

40

ETA

10

12

4

11

4

100

5

441

+

+

25

Deceased

A. baumannii

41

Blood

10

12

4

11

4

100

5

441

+

+

25

Discharged

A. baumannii

45

ETA

10

12

4

11

4

98

5

231

+

+

20

Deceased

A. baumannii

12

ETA

12

17

12

1

29

102

39

236

+

+

35

Deceased

A. baumannii

17

ETA

12

17

12

1

29

102

39

236

+

+

35

Deceased

A. baumannii

2

ETA

24

92

96

11

49

162

26

499

+

+

20

Discharged

A. baumannii

6

ETA

24

92

96

11

49

162

26

499

+

+

25

Deceased

A. baumannii

7

ETA

24

92

96

11

49

162

26

499

+

+

20

Deceased

A. baumannii

13

ETA

24

92

96

11

49

162

26

499

+

+

15

Deceased

A. baumannii

15

ETA

24

92

96

11

49

162

26

499

+

+

15

Deceased

A. baumannii

39

ETA

24

92

96

11

49

162

26

499

+

+

35

Deceased

A. baumannii

42

Blood

24

92

96

11

49

162

26

499

+

+

25

Deceased

A. baumannii

50

Swab

24

92

96

11

49

162

26

499

+

+

20

Deceased

A. baumannii

43

Blood

28

38

45

1

16

66

2

1089

+

25

Deceased

A. baumannii

9

ETA

44

73

No gene

11

44

4

NA

+

+

40

Deceased

A. baumannii

10

ETA

44

73

No gene

11

44

4

NA

+

+

20

Discharged

ETA endotracheal aspirate, + positive, − negative

a New sequence type (ST13929)

 gpi 173, 1 difference found. 33T → 33C

Fig. 2

Phylogenetic tree of 50 A. baumannii strains built based on the maximum likelihood algorithm in the MEGA6 software [11] and the concatenated alleles of seven housekeeping genes with bootstrap values. The phylogenetic analysis identified ST195, ST208, ST231, ST441, ST499, and ST723 and the new sequence type ST13929. The numbers in the branches depict the sample ID of A. baumannii

Discussion

MDR A. baumannii is a problematic, multidrug-resistant pathogen identified in healthcare settings worldwide, especially in ICUs [12]. A. baumannii has a notable ability to capture and express resistance genes. All resistance mechanisms including target modification, efflux pump expression, and enzymatic inactivation have been described in A. baumannii [13].

In the current study, five MDR A. baumannii strains were isolated over 1 week from the same ICU. All isolates showed the same phenotypic characteristics which prompted us to start a survey study of the antimicrobial susceptibility and clonal relationship of A. baumannii strains isolated from this ICU.

All our isolates were resistant to imipenem. The main role of the A. baumannii resistance to carbapenems is mediated by oxacillinases and, less frequently, by metallo-β-lactamases [4, 5].

bla OXA-23-like, bla OXA-24/40-like, and bla OXA-58-like genes have been repetitively reported in A. baumannii outbreaks from diverse parts of the world. The localization of numerous β-lactamase genes on plasmids facilitates their horizontal mobilization from one bacterium to another [13, 14].

All our isolates harbored the bla OXA-51-like gene, which is ubiquitous in A. baumannii [15]. bla OXA-23 was the most universally identified gene, while bla OXA-24-like and bla OXA-58-like genes were not detected in any strain. bla OXA-23 is the most prevalent carbapenemase-encoding gene in the Mediterranean region. This might be explained by the higher carbapenemase activity of bla OXA-23 and/or acquisition of carbapenem resistance through horizontal gene transfer [1618]. The bla OXA-23 gene was either encoded on the chromosome or on plasmids and was associated with four dissimilar genetic structures, with the most common being transposons Tn2006. bla OXA-23 has been reported in different regions of the Middle East, The United Arab Emirates, Algeria, Libya, Bahrain, and recently, Qatar [16, 19].

Mugnier et al. found an isolate from Egypt harboring plasmid containing bla OXA-23. This finding might indicate the prevalence of the genetic environment of bla OXA-23 in Egyptian isolates [16]. Moreover, a recent study including three Egyptian hospitals revealed the emergence and spread of bla NDM-1 and bla OXA-23 in addition to the co-occurrence of 16S rRNA methylase armA with bla NDM-1 and bla OXA-23 in 27 distinct sequence types, 11 of which were novel among A. baumannii clinical isolates [20].

Per MLST results, ST195, ST208, ST231, ST441, ST499, and ST723 were the most prevalent isolates. Another Egyptian study illustrated the large diversity found within the strains where ten distinct sequence types (STs) were identified, ST408–ST414, ST331, ST108, and ST208 [21]. However, a study showed that the most prevalent sequence types in the gulf area were ST195, ST208, ST229, ST436, ST450, ST452, and ST499 [22].

Taking into consideration that ST208 is the ancestor strain of several STs including ST89, ST88, ST190, ST225, and ST75, it has been identified in different parts of the world such as Japan, China, Thailand, Korea, Italy, Australia, Portugal, and the Czech Republic [23].

In conclusion, MDR A. baumannii strains harboring the bla OXA 23-like gene were widely circulating in our ICU. MLST provided us with a powerful tool for identifying and epidemiologically typing our strains. Studying the epidemiology of HAIs is urgent to prevent the clonal dissemination of antibiotic-resistant pathogens, not only in hospital settings, but in the community, as well. Strict infection control measures and antimicrobial stewardship programs are necessary to contain the worldwide spread of MDR A. baumannii. Proving the clonal relation between clinical isolates emphasizes the importance of surveillance programs and strict IC measures that would influence decision-making and health policy.

Declarations

Authors’ contributions

DG, and MA conceived and designed the study, carried out the collection of the bacterial strains, participated in antibiotic sensitivity and molecular genetic studies. DG drafted the manuscript. MZ participated in antibiotic sensitivity, and MHA. EA and RB carried out the MLST and participated in the design of the study. OA participated in the antimicrobial sensitivity testing and multiplex PCR. All authors read and approved the final manuscript.

Acknowledgements

The authors extend their appreciation to the Deanship of Scientific Research at King Saud University for funding the study through research group project no. RGP-038.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The raw data of this research can be made available to the interested researchers if requested.

Ethics approval

Ethical Committee of faculty of medicine, Cairo University approved the study and a written informed consent was not obtained from patients because the bacterial isolates studied were collected from the routine work of microbiology laboratory for patient care and no additional clinical specimens were collected for the study. It is a standard practice not to get written informed consent for use of bacterial isolates unlinked to patient identity from the routine clinical laboratory.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University
(2)
Department of Microbiology and Immunology, Faculty of Pharmacy, Ahram Canadian University
(3)
Department of Pharmaceutics, College of Pharmacy, King Saud University
(4)
Department of Microbiology and Immunology, Faculty of Pharmacy, Al-Azhar University
(5)
National Center for Biotechnology, King Abdulaziz City for Science and Technology
(6)
Department of Microbiology, Faculty of Science, Zagazig University

References

  1. Ghaith DM, Hassan RM, Hasanin AM. Rapid identification of nosocomial A. baumannii isolated from a surgical intensive care unit in Egypt. Ann Saudi Med. 2015;36(5):440–4.View ArticleGoogle Scholar
  2. Hasanin A, Mukhtar A, El-Adawy A, Elazizi H, Lotfyn A, Nassar H, Ghaith D. Ventilator associated pneumonia caused by extensive-drug resistant Acinetobacter species: colistin is the remaining choice. Egypt J Anaesth. 2016. doi:10.1016/j.egja.2016.03.004.Google Scholar
  3. Helal S, El Anany M, Ghaith D, Rabeea S. The role of MDR- A. baumannii in orthopedic surgical site infections. Surg Infect. 2015. doi:10.1089/sur.2014.187.Google Scholar
  4. Poirel L, Nordmann P. Carbapenem resistance in A. baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006;12:826–36.View ArticlePubMedGoogle Scholar
  5. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem resistant A. baumannii. J Antimicrob Chemother. 2010;65:233–8.View ArticlePubMedGoogle Scholar
  6. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of A. baumannii by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol. 2006;44:2974–6.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. Document M100-S25. Wayne: CLSI; 2015.
  8. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.View ArticlePubMedGoogle Scholar
  9. Woodford N, Ellington M, Coelho J, Turton J, Ward M, Brown S, Amyes S, Livermore D. Multiplex PCR for genes encoding prevalent OXA Carbapenemases in Acinetobacter spp. Int J Antimicrob Agents. 2006. doi:10.1016/j.ijantimicag.2006.01.004.PubMedGoogle Scholar
  10. Alyamani EJ, Khiyami MA, Booq RY, Alnafjan BM, Altammami MA, Bahwerth FS. Molecular characterization of extended-spectrum beta-lactamases (ESBLs) produced by clinical isolates of Acinetobacter baumannii in Saudi Arabia. Ann Clin Microbiol Antimicrob. 2015. doi:10.1186/s12941-015-0098-9.PubMedPubMed CentralGoogle Scholar
  11. Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: molecular evolutionary genetics analysis version 6.0. Mol Biol Evol. 2013. doi:10.1093/molbev/mst197.PubMedPubMed CentralGoogle Scholar
  12. Hasanin A, Eladawy A, Mohamed H, Salah Y, Lotfy A, Mostafa H, Ghaith D, Mukhtar A. Prevalence of extensively drug-resistant gram negative bacilli in surgical intensive care in Egypt. Pan Afr Med J. 2014. doi:10.11604/pamj.2014.19.177.4307.Google Scholar
  13. Higgins PG, Dammhayn C, Hackel M, Seifert H. Global spread of carbapenem-resistant A. baumannii. Br Soc Antimicrob Chemother. 2010. doi:10.1093/jac/dkp428.Google Scholar
  14. Djahmi N, Dunyach-Remy C, Pantel A, Dekhil M, Sotto A, Lavigne JP. Epidemiology of carbapenemase-producing Enterobacteriaceae and A. baumannii in Mediterranean countries. Biomed Res Int. 2014. doi:10.1155/2014/305784.PubMedPubMed CentralGoogle Scholar
  15. Hamouda A, Evans BA, Towner KJ. Amyes SBG. Characterization of epidemiologically unrelated A. baumannii isolates from four continents by use of multilocus sequence typing, pulsed-field gel electrophoresis, and sequence-based typing of blaOXA-51-like genes. J Clin Microbiol. 2010;48:2476–83.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide dissemination of the blaOXA-23 carbapenemase gene of Acinetobacter Baumannii. Emerg Infect Dis. 2009. doi:10.3201/eid1601.090852.Google Scholar
  17. Minandri F, D’Arezzo S, Antunes LCS, Pourcel C, Principe L, Petrosillo N, Visca P. Evidence of diversity among epidemiologically related carbapenemase-producing Acinetobacter Baumannii strains belonging to international clonal lineage II. J Clin Microbiol. 2011. doi:10.1128/jcm.05555-11.PubMedPubMed CentralGoogle Scholar
  18. Grosso F, Quinteira S, Peixe L. Understanding the dynamics of imipenem-resistant A. baumannii lineages within Portugal. Clin Microbiol Infect Dis. 2011. doi:10.1111/j.1469-0691.2011.03469.x.Google Scholar
  19. Rolain JM, Loucif L, Al-Maslamani M, Elmagboul E, Al-Ansari N, Taj-Aldeen S, et al. Emergence of multidrug-resistant A. baumannii producing OXA-23 carbapenemase in qatar. New Microbes New Infect. 2016. doi:10.1016/j.nmni.2016.02.006.Google Scholar
  20. El-Sayed MAEG, Amin MA, Tawakol WM, Loucif L, Bakour S, Rolain JM. High prevalence of blaNDM-1 carbapenemase-encoding gene and 16S rRNA armA methyltransferase gene among Acinetobacter baumannii clinical isolates in Egypt. Antimicrob Agents Chemother. 2015. doi:10.1128/AAC.04412-14.Google Scholar
  21. Al-Hassan L, El Mehallawy H, Amyes SG. Diversity in Acinetobacter baumannii isolates from paediatric cancer patients in Egypt. Clin Microbiol Infect. 2013. doi:10.1111/1469-0691.12143.PubMedGoogle Scholar
  22. Zowawi HM, Sartor AL, Sidjabat HE, Balkhy HH, Walsh TR, Al Johani SM, et al. Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii isolates in the Gulf Cooperation Council states: dominance of OXA-23-type producers. J Clin Microbiol. 2015. doi:10.1128/JCM.02784-14.Google Scholar
  23. Liu F, Zhu Y, Yi Y, Lu N, Zhu B, Hu Y. Comparative genomic analysis of Acinetobacter baumannii clinical isolates reveals extensive genomic variation and diverse antibiotic resistance determinants. BMC Genomics. 2014. doi:10.1186/1471-2164-15-1163.Google Scholar

Copyright

© The Author(s) 2017

Advertisement